Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688336's PB Ratio is ranked worse than 65.85% of 1230
companies
in the Biotechnology industry
Industry Median: 2.75
vs SHSE:688336: 4.16
During the past 12 months, Sunshine Guojian Pharmaceutical (Shanghai) Co's average Book Value Per Share Growth Rate was 51.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 22.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sunshine Guojian Pharmaceutical (Shanghai) Co was 35.70% per year. The lowest was 2.40% per year. And the median was 18.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sunshine Guojian Pharmaceutical (Shanghai) Co PB Ratio Related Terms
Sunshine Guojian Pharmaceutical (Shanghai) Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co PB Ratio Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co PB Ratio vs Biotechnology Industry
Sunshine Guojian Pharmaceutical (Shanghai) Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a PB Ratio of 4.17 as of Aug. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. This is 54% above median its historical median of 2.70. Over the past decade, Sunshine Guojian Pharmaceutical (Shanghai) Co's PB Ratio has ranged from 1.67 to 9.13. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #810 out of 1230 companies in the Biotechnology industry, placing it in the top 65.9%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's PB Ratio too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current PB Ratio of 4.17 is 54% above median its 10-year median of 2.70. Over the past 10 years, this metric has ranged from a low of 1.67 to a high of 9.13. The Biotechnology industry median PB Ratio is 2.75. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 4.17 is 51.6% above this industry median. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #810 out of 1230 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #810 out of 1230 companies for PB Ratio. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the lower half of its industry. The industry median PB Ratio is 2.75. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 4.17 is 51.6% above this benchmark. Historically, Sunshine Guojian Pharmaceutical (Shanghai) Co's own PB Ratio has ranged from 1.67 to 9.13 over the past decade. While the company's 10-year median is 2.70 vs. the industry median of 2.75, Sunshine Guojian Pharmaceutical (Shanghai) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Guojian Pharmaceutical (Shanghai) Co's current PB Ratio of 4.17 is 51.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current PB Ratio is 4.17, which is 54% above median its own 10-year median of 2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Possible Value Trap. The stock's GF Value™ is ¥67.68, compared to a current price of ¥40.06 — trading 40.8% below its estimated fair value. The current PB Ratio is 4.17, which is 54% above median its 10-year median of 2.70 and 51.6% above the Biotechnology industry median of 2.75. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current PB Ratio is 4.17 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥40.06 is trading 40.8% below its estimated GF Value™ of ¥67.68.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Possible Value Trap.
Key valuation signals for SHSE:688336:
PB Ratio: 4.17 (54% above median its 10-year median of 2.70)
GF Value™: ¥67.68 vs. price of ¥40.06 (40.8% below fair value)
Industry Position: 51.6% above the Biotechnology median (#810 of 1230)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
75GF Score
Get the complete analysis for SHSE:688336
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
